Facet Biotech Reports Elotuzumab Data (NASDAQ:FACT)
Facet Biotech Corporation (NASDAQ:FACT) along with Bristol-Myers Squibb Company have announced that the interim data from the study of elotuzumab is promising. CEO and President of Facet Biotech, Faheem Hasnain mentioned that the preliminary data showed that elotuzumab in combination with lenalidomide and dexamethasone may have potential as a treatment option for patients with multiple myeloma and also that they are working closely with their partners at Bristol-Myers Squibb to finalize next steps for the elotuzumab development program, and anticipate initiating a global Phase II study in the first half of 2010.
Facet Biotech is a biotechnology company which is dedicated to advancing its pipeline of five clinical-stage products, leveraging its research and development capabilities to identify and develop new oncology drugs and applying its proprietary next-generation protein engineering technologies to potentially improve the clinical performance of protein therapeutics. Elotuzumab is a humanized monoclonal antibody directed against CS1, a cell-surface glycoprotein that is highly and uniformly expressed on multiple myeloma cells but is minimally expressed on normal cells.
The ongoing Phase I/II study of elotuzumab plus lenalidomide and low-dose dexamethasone evaluated multiple doses of elotuzumab in patients with multiple myeloma. The interim results given as an oral presentation today showed that of the 28 treated patients in the trial, 23 (82 percent) had an objective response by International Myeloma Working Group (IMWG) criteria. Another subset analysis showed that of 22 patients who had not previously received lenalidomide treatment, 21 patients (95 percent) achieved an objective response. The study is also evaluating safety, pharmacokinetics (PK) and clinical response.
Tags: FACT
Related Articles:
